Friday, June 05, 2015 3:50:23 AM
Brachytherapy treatments can be effective for various head and neck cancers. One type of brachytherapy called low-dose-rate (LDR) brachytherapy is performed by permanently or temporarily implanting radioactive seeds in the cancerous tissue so they can give off their radiation dose for days or months. Another type, called high dose rate (HDR) brachytherapy, uses a highly radioactive source that is temporarily placed near the target area to quickly give a high dose and then removed.
Low-Dose-Rate (LDR) Brachytherapy: We continue to offer LDR permanent seed implants using the isotope Iodine-125 (I-125) to deliver the therapeutic radiation dose. However, recently NewYork-Presbyterian Radiation Oncology became the first in the nation to use a new isotope called Cesium-131 (Cs-131) for one type of head and neck cancer. Cs-131 delivers the therapeutic dose much more quickly then I-125 — weeks instead of months — and has other characteristics that may give superior outcomes depending on the needs of the patient.
More commonly, temporary implants using LDR Iridium-192 (Ir-192) are used as appropriate.
High-Dose-Rate (HDR) Brachytherapy: We also offer highly specialized HDR treatments for certain head and neck cancers including cancers of the tongue. Because of the specialized nature of these treatments, they are only available at a few other centers in the nation.
http://www.nyp.org/radonc/head-neck.html
Recent CATX News
- Perspective Therapeutics to Participate at Upcoming April Investor Conferences • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024 • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Perspective Therapeutics Announces $87.4 Million Private Placement • GlobeNewswire Inc. • 03/04/2024 02:45:00 PM
- Perspective Therapeutics to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement • GlobeNewswire Inc. • 01/22/2024 09:05:00 PM
- Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement • GlobeNewswire Inc. • 01/18/2024 12:00:00 PM
- Perspective Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 01/17/2024 09:05:00 PM
- Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01 • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Another Healthcare Stock Stealing The Show • AllPennyStocks.com • 01/09/2024 09:10:00 PM
- Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment • GlobeNewswire Inc. • 01/05/2024 01:00:00 PM
- Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Perspective Therapeutics Divests Brachytherapy Business • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM